The Cholesteryl Ester Transfer Protein (CETP) raises Cholesterol Levels in the Brain and affects Presenilin-mediated Gene Regulation.

Running title: CETP increases brain cholesterol and γ -secretase activity

Felix Oestereich^{1,2,3}, Noosha Yousefpour¹, Ethan Yang⁴, Alfredo Ribeiro-da-Silva¹, Pierre Chaurand⁴, Lisa Marie Munter^{1,2}

¹Department of Pharmacology and Therapeutics, McGill University, 3649 Promenade Sir William Osler, Montreal, QC, Canada H3G 0B1

²Cell Information Systems group, Bellini Life Sciences Complex, 3649 Promenade Sir William Osler, Montreal, QC, Canada H3G 0B1

³Integrated Program in Neuroscience, McGill University, Montreal, QC, Canada H3A 2B4

⁴Department of Chemistry, Université de Montréal, Montreal, QC, Canada H3C 3J7

Correspondence: Dr. Lisa Munter, lisa.munter@mcgill.ca, McGill University, Department of Pharmacology and Therapeutics, Bellini Life Sciences Complex, 3649 Promenade Sir-William Osler, Montreal, QC, Canada, H3G 0B1

Funding: This work was funded by the Alzheimer Society of Canada Young Investigator grant PT-58872 and regular Research Grant 17-02, the Weston Brain Institute award RR172187, and the Canadian Institute of Health Research CIHR-PJT-162302, and was supported by the Fonds de recherche du Québec - santé FRQS research allocation FRQ-S 36571, the Canada Foundation of Innovation Leaders Opportunity Fund Grant 32565, and Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grants RGPIN-2015-04645 to LM and RGPIN-2015-06802 to PC. ARdS acknowledges support from CIHR project grant PJT-166195. FO received studentships through the Integrated Program in Neuroscience (IPN) and from the Canada First

27 Research Excellence Fund, awarded to McGill University for the Healthy Brains for Healthy Lives
28 initiative. NY was the recipient of a doctoral studentship from the Louise and Alan Edwards
29 Foundation. EY received a doctoral studentship from NSERC.

Abstract

The cholesteryl ester transfer protein (CETP) is a lipid transfer protein responsible for the exchange of cholesteryl esters and triglycerides between lipoproteins. Decreased CETP activity is associated with longevity, cardiovascular health, and maintenance of good cognitive performance. Interestingly, mice lack the CETP-encoding gene and have very low levels of low-density lipoprotein (LDL) particles compared to humans. To understand how CETP activity affects the brain, we utilised CETP transgenic (CETPtg) mice showing elevated LDL levels on a high cholesterol diet inducing CETP expression. We found that CETPtg mice had up to 25% higher cholesterol levels in the brain. Using a microarray on astrocyte-derived mRNA, we found that this cholesterol increase is likely not due to astrocytic-dependent *de novo* synthesis of cholesterol. Rather, several genes linked to Alzheimer's disease were altered in CETPtg mice. Most interestingly, we found activation of the G-protein coupled receptor EP4 and γ -secretase as upstream regulators of these transcriptional changes. Further *in vitro* studies showed that CETP expression was sufficient to activate γ -secretase activity. The data suggest that CETP activity affects brain's health through modulating cholesterol levels and Alzheimer's-related pathways. Therefore, CETPtg mice constitute a valuable research tool to investigate the impact of the cholesterol metabolism on brain functions.

Key words:

Alzheimer's disease, cholesteryl ester transfer protein (CETP), cholesterol, gamma-secretase, presenilin, mass spectrometry, microarray, brain lipids, complement system, C1Q, prostaglandin receptor EP4, TREM2.

Introduction

Cholesterol is a major constituent of biomembranes and precursor for various hormones. In most tissues, the cholesterol concentration is about 2 mg/g tissue, however, it reaches 15-20 mg/g in tissue of the central nervous system (CNS) (1). Thus, the brain contains 25% of the total body cholesterol, suggesting a special need of the brain for cholesterol (2). In the blood, dietary cholesterol is transported by very-low density lipoprotein (VLDL) or low-density lipoprotein (LDL) particles that are secreted by the liver to deliver cholesterol to extrahepatic tissues (3). Reverse cholesterol transport from the periphery back to the liver occurs via high-density lipoprotein (HDL) particles (4). However, the brain seems to be excluded from these distribution cycles since neither VLDL or LDL particles cross the blood-brain barrier (2,5-7). In the CNS, astrocytes are the cell type primarily involved in lipid synthesis and secrete HDL-like lipoprotein particles that contain predominantly apolipoprotein E (ApoE) as the apolipoprotein (8). Such particles are taken up by neurons through members of the LDL-receptor family that recognise ApoE including the LDL-receptor related protein 1 (LRP1) (9).

The cholesteryl ester transfer protein (CETP) is a lipid transfer protein that facilitates the exchange of cholesteryl esters in HDL for triglyceride in VLDL and LDL (10,11). The net result of this transfer activity is increased cholesterol content in pro-atherogenic LDL particles and decreased cholesterol levels in anti-atherogenic HDL particles (12). Studies investigating the genetic predisposition of “super-agers” or “centenarians” with well-maintained health and cognitive performance, revealed that polymorphisms that impair CETP’s activity associate with longevity, cardiovascular health, and good cognitive performance (13-15). Based on these findings, several studies investigated whether CETP polymorphisms could decrease the risk for Alzheimer’s disease, an aging-associated neurodegenerative disease. Indeed, protective effects of CETP polymorphisms at *early* Alzheimer’s disease stages were reported, particularly in carriers of the strongest genetic risk factor, the $\epsilon 4$ allele of the apolipoprotein E (ApoE4) (16-19). ApoE is the predominant lipoprotein of the brain, in contrast to the blood where there are several apolipoprotein-defined lipoprotein families (20). Those

epidemiological findings indicate that CETP activity may impact on cognitive performance and brain functions, however, the underlying molecular mechanisms remain unclear.

While CETP is predominantly expressed in the liver and secreted to the blood, it is expressed in astrocytes as well (21). However, its function in the CNS remains elusive. Considering the important effect of CETP on systemic cholesterol levels, we hypothesised that CETP may also contribute to the alterations of the brain's cholesterol levels. It is important to note that mice naturally lack CETP and therefore they have considerably less LDL compared to humans (22). To gain insight on how CETP may impact on cognitive performance in humans, we used a well-established CETP^{tg} mouse model expressing the human CETP gene under its natural promoter (CETP^{tg}) that is frequently used in the cardiovascular research field (23). The promoter contains a cholesterol responsive element that induces CETP gene expression in response to dietary lipids. Therefore, CETP expression in CETP^{tg} mice leads to increased LDL levels and could thus be regarded as a mouse model with a humanised (normolipidemic) lipoprotein profile (24). We herein characterised the effects of CETP expression on molecular changes in the brain in CETP^{tg} mice. We observed higher cholesterol levels in the brains of CETP^{tg} as compared to wild type (wt) mice. Transcriptome profiling of astrocytes indicated decreased cholesterol synthesis, and modulation of several genes linked to Alzheimer's disease including an overall activation of presenilin-mediated signaling.

Methods:

All experiments were conducted in accordance with McGill University environmental health and safety regulations (EHS) as well as the Canadian biosafety standards and guidelines.

Cell culture: HEK293T cells were cultivated in 1:1 Dulbecco's modified Eagle medium (DMEM) supplemented with 0.584 g/l L-glutamine and 0.11 g/l sodium pyruvate (Wisent), and 10% FCS (Wisent), at 37°C and 5% CO₂. For transient transfections, 1.5 x 10⁵ cells per well (12-well plates) were seeded 24 h before transfection. Cells were transiently transfected with 1 µg DNA in total and 2

µl polyethyleneimine (PEI) per well. 36 hours after transfection, cell culture supernatant was collected, and cells were lysed with TNE-lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP40, and complete protease inhibitors, Roche) and prepared for SDS-polyacrylamide gel electrophoresis (SDS-PAGE).

Western blot analysis of mouse tissue samples:

Fresh frozen liver or brain samples (approximately 100 mg) were lysed in 5x volume of lysis buffer (150 mM NaCl, 10% Glycerol, 2 mM EDTA, 0.5% NP-40, 0.1% sodium-deoxycholate, 20 mM HEPES, 1x complete protease-inhibitor cocktail (Roche), pH 7.4) using lysing-matrix D at 6000 rpm for 40 seconds. The lysates were further diluted 1:5 in lysis buffer. For western-blot analysis, liver samples were prepared for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and loaded on either 10% or 15% SDS-polyacrylamide gels. The following primary antibodies were used: 22C11 (Millipore), rabbit-anti-GAPDH (14C10, Cell Signaling), TP2 (kind gift of the Ottawa Heart Institute), anti-TREM2 (Mab1729 R&D systems) and anti-ABCA7 (polyclonal, Thermo Fisher). Horseradish peroxidase (HRP)-coupled secondary antibodies directed against mouse or rabbit IgG were purchased from Promega. Chemiluminescence images were acquired using the ImageQuant LAS 500 system (GE Healthcare).

Quantitative real time PCR (RT-qPCR):

mRNA was isolated from mouse tissue using the Macherey & Nagel mRNA-isolation kit in combination with lysing matrix D. Briefly, 25-50 µg of fresh frozen tissue were lysed in 450 µL RNA preparation buffer (with β-mercaptoethanol) in lysing matrix D tubes using a magna lyser (6000 rpm 2x 30 seconds) according to manufacturer's instructions. The RNA concentration was adjusted to 100 pg/mL and 500 ng of RNA were transcribed into cDNA using the high-capacity cDNA reverse-transcription kit (Applied Biosystems) according to manufacturer's instructions. RT-qPCR was performed using the SsoAdvanced SYBR green supermix (Biorad) according to manufacturer's instructions on a Biorad CFX384Touch cycler. All primers were ordered from integrated DNA technologies. Primers used were: CETP forward: CAGATCAGCCACTTGTCCAT, CETP reverse: CAGCTGTGTGTTGATCTGGA, ABCA7 forward: TTCTCAGTCCCTCGTCACCCAT, ABCA7 reverse: GCTCTTGTCTGAGGTTTCCTCGT, TNFα

129 forward: GGTGCCTATGTCTCAGCCTCTT, TNF α reverse: GCCATAGAACTGATGAGAGGGAG,
 130 IL1 β forward: TGGACCTTCCAGGATGAGGACA IL1 β reverse: GTTCATCTCGGAGCCTGTAGT,
 131 TLR4 forward: AGCTTCTCCAATTTTTCAGAACTTC, TLR4 reverse:
 132 TGAGAGGTGGTGTAAGCCATGC, TREM2 forward: ACAGCACCTCCAGGAATCAAG, TREM2
 133 reverse: AACTTGCTCAGGAGAACGCA, IL6 forward: CCTCTGGTCTTCTGGAGTACC, IL6 reverse:
 134 ACTCCTTCTGTGACTCCAGC, HES1 forward: p21 forward: GCCTTAGCCCTCACTCTGTG p21
 135 reverse: AGCTGGCCTTAGAGGTGACA, HES1 forward: CGGAATCCCCTGTCTACCTC, HES1
 136 reverse: AATGCCGGGAGCTATCTTTCT. The following primers were used as reference genes:
 137 HPRT forward: CCAGTTTCACTAATGACACAAACG, HPRT reverse:
 138 CTGGTGAAAAGGACCTCTCGAAG, PSMC4 forward: CCGCTTACACACTTCGAGCTGT, PSMC4
 139 reverse: GTGATGTGCCACAGCCTTTGCT, GAPDH forward: CATCACTGCCACCCAGAAGACTG,
 140 GAPDH reverse: ATGCCAGTGAGCTTCCCGTTTCAG, Actin- β forward:
 141 CATTGCTGACAGGATGCAGAAGG, Actin- β reverse: TGCTGGAAGGTGGACAGTGAGG. Primer
 142 efficiency for all primers was determined to be between 90-110%. For normalization of gene
 143 expression, the four genes ACT, GAPDH, HPRT and PSMC4 were used as reference genes. RT-
 144 qPCR was analysed using the CFX manager software (Biorad).

145 **Imaging mass spectrometry (IMS):** Sample preparation: The fresh frozen brain samples were
 146 sectioned sagittally at 14 μ m thickness and the frozen brain homogenates at 20 μ m thickness with a
 147 Leica CM3050 cryostat at -20°C (Leica Microsystems GmbH, Wetzlar, Germany). All brain
 148 specimens were cut at approximately the same Bregma in order to clearly delineate the hippocampus.
 149 Brain homogenates were prepared according to published protocols (25) and were used to normalise
 150 data across experiments. For each technical replicate, one tissue section of each condition was thaw-
 151 mounted in a 2 x 2 pattern on a 25 x 75 mm indium-tin-oxide (ITO) coated microscope slide (Delta
 152 Technologies, Loveland, CO), along with two sections of frozen brain homogenate on the left and
 153 right of the grid. After desiccation in a vacuum pump desiccator for $\leq$ 1 hour, a 23 ± 2 nm silver layer
 154 was deposited onto the sections using a Cressington 308R sputter coater (Ted Pella Inc, Redding,

CA) as per the protocol detailed in Dufresne et al 2013 (26). The argon partial pressure was set at 0.02 mbar and the current at 80 mA. Data acquisition: IMS data were acquired at 50 μm spatial resolution and 100 shots per raster position with a “small” laser setting using a “matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF/TOF) ultrafleXtreme mass spectrometer (Bruker Daltonics, Billerica, MA) equipped with a SmartBeam-II Nd:YAG/355-nm laser operating at a repetition rate of 1 kHz using flexImaging 4.1 software (Bruker Daltonics, Billerica, MA). All instrumental parameters (source voltages, laser energy, delayed extraction parameters, etc.) were optimised for maximum signal-to-noise ratio within the 100-1100 m/z range in the reflectron geometry, with the acceleration voltage set to 25 kV. Two 400-pixel squares were also acquired from each brain tissue homogenate section at the same spatial resolution. Data Analysis: Raw IMS data were first internally calibrated with the silver isotopic peaks using the flexAnalysis Batch Process software (Bruker Daltonics, Billerica, CA) to obtain a ~ 5 ppm mass accuracy. Next, IMS data from the hippocampal and whole brain regions of interests (ROIs) were exported into the common imzML format using flexImaging 4.1 (27). Using an in-house code based on the Cardinal package (x1.6.0) in R (x3.2.5), the mean area and standard deviation of the two cholesterol signals (m/z 493.26 and m/z 495.26, corresponding to the $[\text{M}+^{107}\text{Ag}]^+$ and $[\text{M}+^{109}\text{Ag}]^+$ molecular ions, respectively) were calculated for the ROIs after independent TIC normalization (28). The same code was used to obtain the mean of the summed areas of the ten most abundant signals in the homogenate squares. This value acted as the correction factor to correct for variations in signal intensity across all experiments. The final cholesterol intensity reported is the mean across the three technical triplicates for one group normalised against the correction factor. Unless otherwise noted, all solvent and material were purchased from Thermo Fisher Scientific (Ottawa, ON). The silver target 3N5 (99.95% purity) used for tissue sputter-coating was purchased from ESPI Metals (Ashland, OR).

Filipin staining and Immunohistochemistry: Fresh-frozen brains were cut on the sagittal plane at 25 μm thickness using a cryostat (Leica, Germany). Sections were then collected and fixed in 4% paraformaldehyde at 4°C for two hours. Filipin III (stock powder) was dissolved at a concentration of 10

181 mg/ml in dimethylformamide (DMF) and diluted 100-fold with 10 mM phosphate buffered saline (PBS).
 182 For Filipin staining, tissues were washed in PBS and incubated in 0.01 mg/ml Filipin complex solution
 183 (Sigma Aldrich) at room temperature for two hours. After washing with PBS, brain sections were mounted
 184 on a microscope slide and imaged with Zeiss AxioImager M2 Imaging microscope with the Zeiss ZenPro
 185 software v.2.3 (Zeiss Canada). For Immunohistochemistry, brain sections were permeabilized with 0.2%
 186 Triton-X in PBS (PBST) and blocked for 1 hour at room temperature in 10% normal donkey or goat serum.
 187 Sections were incubated in a cocktail of primary antibodies composed of mouse anti-GFAP (Cell signaling,
 188 cat # 3670, 1:1000), and rabbit anti-C1q (Abcam, cat # ab182451, 1:400) prepared in 5% blocking solution
 189 for 12 h at 4°C. Primary antibody labelling was detected using species-specific secondary antibodies
 190 conjugated to Alexa 488, and Alexa 568 (Invitrogen, 1:800, incubated at room temperature for 2 hours).
 191 Sections were mounted on gelatin subbed slides and coverslipped using Prolong Gold Antifade mounting
 192 medium (Invitrogen) and Zeiss cover slips. Sections were imaged using Zeiss LSM 800 confocal
 193 microscope. For image analysis, Filipin and C1q fluorescence intensity levels were quantified by the
 194 average intensity of staining in ImageJ (NIH) using images captured by 20x objective (C1q) and 40x
 195 objective (filipin). Specifically for filipin staining, all images were thresholded to an equal value that was
 196 determined empirically and only fluorescent intensities corresponding to the cell membranes were
 197 quantified. All values were normalized to the background fluorescence of the corresponding image.

198 **Mouse housing:** The CETP^{tg} mouse strain B6.CBA-Tg(CETP)^{5203Tall/J} (Jackson strain no.:
 199 003904) (23) were housed according to the McGill University standard operating procedure mouse
 200 breeding colony management #608. All procedures were approved by McGill's Animal Care
 201 Committee and were performed in accordance with the ARRIVE guidelines (Animal Research:
 202 Reporting in Vivo Experiments). Mice were bred heterozygous and non-transgenic littermates were
 203 used as controls. Mice of both sexes were used in analyses at about equal ratios. All mouse diets
 204 were purchased from Envigo. The diets used in this study were: low fat control diet (TD.08485), low
 205 fat diet enriched with 1% cholesterol (TD.140215) and a diet containing 21% fatty acids (FA) and 1%
 206 cholesterol (TD.95286). The FA composition was 65% saturated FA (SFA), 31% monounsaturated

207 FA (MUFA), and 4% polyunsaturated FA (PUFA). Animals of both sexes were assigned randomly to
208 treatment groups.

209 **Mouse genotyping:** Genotyping was performed by Transnetyx genotyping using real-time PCR from
210 ear punch tissue. Ear punches were lysed in at 56 °C overnight. Primers used for the transgene were:
211 forward: GAATGTCTCAGAGGACCTCCC, reverse: CTTGAACTCGTCTCCCATCAG. Primers for
212 internal controls were: Forward: CTAGGCCACAGAATTGAAAGATCT, reverse:
213 GTAGTGGAAATTCTAGCATCATCC.

214 **Plasma lipid analysis:** The lipid analysis of mouse plasma samples was performed using the COBAS
215 Integra 400 Plus (ROCHE) and the following kits: COBAS INTEGRA CHOL 2, COBAS INTEGRA
216 HDL-C gen3, and COBAS Integra TRIG GPO 250, respectively. The levels of LDL-C were calculated
217 using the Friedewald formula: [total cholesterol] – [HDL-C] – [TG/2.2].

218 **CETP activity assay:** CETP activity was measured using the Roar biomedical Inc. fluorescent CETP
219 activity assay. Here, 5 µL of cell culture supernatant was incubated with 0.3 µL donor and 0.3 µL
220 acceptor molecules in 30 µL reaction volume. The reaction mix was incubated for 3 hours at 37 °C in
221 a water bath and the fluorescence (λ_{ex} 465/ λ_{em} 535) was measured.

222 **Astrocyte purification:** Astrocytes were purified using the Anti-GLAST (ACSA-1) MicroBead Kit
223 (Miltenyi biotec). Briefly, whole mouse brains were dissociated using a miltenyi gentleMACS Octo
224 dissociator with Heaters, and GLAST positive astrocytes were isolated using anti-GLAST (ACSA-1)
225 antibody magnetic beads according to manufacturer's instructions.

226 **Flow cytometry:** Purified astrocytes were EtOH fixed and stained with a Cy3 labelled anti-GFAP
227 antibody (1:1000, Sigma). The samples were run on a BD LSRFortessa flow cytometer and the GFAP-
228 Cy3 emission was detected using a 561 nm laser for excitation. The detector channel used was
229 586/15 nm. BD FACSDIVA 8.0.1. was used for analysis.

230 **Astrocyte microarray:** RNA from GLAST-positive astrocytes was isolated using the Macherey &
231 Nagel mRNA isolation kit. The Affymetrix clariom-S nano microarray was performed at the
232 Genomecenter Quebec according to manufacturer's instructions. The initial microarray dataset was

233 analysed using Transcriptome Analysis Software (Affymetrix). Upstream regulator and pathway
 234 analyses were performed using Ingenuity Pathway Analysis (IPA). GEO accession number:
 235 GSE111242.

236 **Statistical analysis:** Statistical analysis was performed using the Graphpad Prism 7 and 8 software.
 237 Analyses include only parametric tests: students T-test, and two-way ANOVA followed by Bonferroni
 238 corrections and Tukey's multiple comparison tests. All p values, statistical tests, N values and the
 239 experimental unites employed are indicated in figure legends.

240

241

Results:

Dietary cholesterol intake induces CETP expression

CETP^{tg} animals have been widely used in cardiovascular research (23). However, it remained unclear if fatty acids further induce CETP expression in addition to dietary cholesterol. To identify the ideal diet for inducing CETP expression in the CETP^{tg} model, we compared a diet enriched with 1% (w/w) cholesterol to a diet containing 1% cholesterol plus 21% (w/w) fatty acids (cholesterol/FA) for their effects on CETP expression in CETP^{tg} mice. Wt and CETP^{tg} mice received diets for one month starting at 2 months of age (**Figure 1A**). As expected, CETP^{tg}, but not wt mice showed CETP activity, confirming that there is no compensatory mechanism for the lack of CETP in wt mice. CETP activity was increased 2-fold in animals that were on a diet enriched in cholesterol or cholesterol/FA as compared to mice on standard diet (**Figure 1B**). Likewise, both high fat diets induced a 2-fold increase of circulating CETP protein levels in mouse plasma, as determined by western blot (**Figure 1D, E**). Further, we quantified CETP mRNA levels in liver by RT-qPCR and found that the diet supplemented only with cholesterol induced a bigger increase of CETP mRNA levels (8.8-fold) as compared to the high cholesterol/FA diet (7-fold) (**Figure 1C**). When assessing the lipid profile in plasma, we found that CETP^{tg} mice had lower HDL levels on standard and high cholesterol diets, an effect that was missing in mice receiving the cholesterol/FA diet (**Figure 1F**). LDL cholesterol levels were significantly elevated in CETP^{tg} animals fed with a cholesterol-enriched diet, which was not observed in animals fed with a cholesterol/FA diet, although both diets led to a similar increase in CETP activity and protein levels (**Figure 1G**). It is important to note that those LDL levels of approximately 1.2 mmol/L observed in CETP^{tg} mice are still relatively low considering that human LDL levels < 3 mmol/L are still being considered healthy levels. Total cholesterol was not significantly affected by the diets (**Figure 1H**). However, we found a trend towards decreased levels of triglycerides in animals fed with the cholesterol diet independent of the genotype (**Figure 1I**). Finally, we analysed the net weight gain of mice during the 4-week diet period. In contrast to the cholesterol/FA diet, mice on the cholesterol diet did not show an additional weight gain as compared to standard diet (**Figure 1J**). Together, high

CETP expression and enhanced activity are achieved with both diets. However, the blood lipoprotein profile only changed towards a more human-like profile, i.e. increased LDL levels, in mice receiving the cholesterol-only diet. In addition, since cholesterol-enriched food did not impact the weight of mice, this diet has the advantage that potentially confounding factors such as obesity can be excluded. Thus, we chose to use the 1% cholesterol diet for further experiments.

CETP promotes TREM2 expression in the liver

To ultimately study the chronic effect of CETP expression on the brain, we expanded the diet period to 3 months (**Figure 2A**). First, we analyzed the effect of CETP on plasma LDL levels and transcriptional changes in the liver. Dietary cholesterol is known to decrease cholesterol synthesis and transcription of genes involved in cholesterol synthesis (the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase, HMGCR) and cholesterol uptake (LDL-receptor, LDLR, and the lipoprotein-receptor-related protein-1, LRP1) through regulation of the sterol regulatory element-binding protein-2 (SREBP-2) (29). Indeed, HMGCR, LDLR, and LRP1 mRNA levels were decreased on high cholesterol diet in wt and CETP^{tg} mice as compared to wt mice on a standard diet at the age of 5 months (**Figure 2 B-D**) (30). In addition, CETP^{tg} mice on a standard diet showed lower HMGCR and LDLR gene expression levels as compared to wt as well, indicating that the little CETP expressed on a standard diet already redistributed cholesterol (**Figure 2 B, C**). Additionally, we assessed two Alzheimer's risk genes, the ATP-binding cassette transporter A7 (ABCA7), a lipid transporter that is also regulated by SREBP-2, and triggering receptor expressed in myeloid cells 2 (TREM2), a lipoprotein receptor (31-34). Protein levels of ABCA7 were increased 2-fold between wt and CETP^{tg} on either diet and the cholesterol diet doubled expression levels (thus a 4-fold difference between the extremes, wt on standard diet compared to CETP^{tg} on cholesterol diet) (**Figure 2E-G**). TREM2 gene transcription was also increased by both the cholesterol diet and CETP expression leading to an 8-fold increase of transcript levels comparing the two extremes (wt mice on standard diet with CETP^{tg} mice on cholesterol diet) (**Figure 2H**). However, this transcript increase could not be replicated at the

protein level, which could be attributed to overall low signal intensities in the western blot (**Figure 2E**, I).

CETP activity promotes peripheral inflammation

It has been previously shown that cholesterol-enriched diets induce inflammation (35). Here we assessed the effect of CETP as well as high cholesterol diet on peripheral inflammation. Specifically, we quantified the inflammatory cytokines IL1 β and TNF α in mouse plasma samples using multiplex ELISA of 5 months old mice after 3 months of a 1% cholesterol or control diet. TNF α levels were significantly increased in CETP^{tg} mice as compared to wt mice on cholesterol diet, however, it should be noted that out of the 10 plasma samples analysed, 6 samples had very low TNF α levels comparable to the control diets, and only 4 mice showed elevated TNF α levels (**Figure 3A**). Levels of IL1 β were slightly increased in several CETP^{tg} mice on the cholesterol diet, and one mouse had much higher levels (**Figure 3B**). Since CETP is mainly secreted by the liver, we determined mRNA expression of such cytokines in the liver by qRT-PCR. As expected, the same mice with elevated plasma cytokine levels also had elevated TNF α and IL1 β mRNA levels in liver (**Figure 3C, D**). Furthermore, mRNA expression of the toll-like receptor 4 (TLR4) as upstream regulator of TNF α and IL1 β was also increased in mice with highest cytokine levels (**Figure 3E**). Similarly, transcript levels of IL6, an interleukin that was reported to induce the expression of lipid regulating proteins were high in 3 out of 12 mice (**Figure 3F**) (36). To analyse whether inflammatory cytokine production was extended to the central nervous system, transcript levels were determined from cortical samples. While we were able to demonstrate that CETP is expressed in the cortex of CETP^{tg} mice, its expression levels were not affected by dietary cholesterol intake (**Figure 3G**). Importantly, cytokine levels were not significantly increased in the brain at this age except for IL1 β levels (**Figure 3H-J**). In summary, CETP expression and a cholesterol diet induced inflammatory responses in the periphery, as expected, with attenuated effects in the brain.

CETP changes the brain cholesterol composition

To determine the effect of CETP expression and high cholesterol diet on the composition and distribution of lipids in the brain, we employed matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS). While several studies have looked at the distribution of lipids in the brain by IMS using 1,5-Diaminonaphthalene or other organic matrices (37,38), the visualization of cholesterol using IMS remained challenging. Here, we deposit a fine homogeneous silver layer over the tissue sections to promote the laser desorption/ionization (LDI) and allow the imaging of cholesterol and olefin containing fatty acids with high specificity and sensitivity (26). The heatmap images depict the distribution of cholesterol in sagittal mouse brain sections detected at m/z 493 ($[M+^{107}Ag]^+$ silver adduct molecular ion) (**Figure 4A**). Cholesterol is found at the highest concentrations in the myelin-rich fibre tracts, whereas lower levels are observed in cortex, hippocampus and cerebellum (**Figure 4A**). Most interestingly, CETPtg mice showed overall higher cholesterol levels in the brain than wt mice with a $23\pm4\%$ increase between wt and CETPtg mice on standard diet and a $31\pm4\%$ increase between wt and CETPtg mice on cholesterol diet over the area of the whole brain (**Figure 4C, D**). The hippocampal region showed similar trends, albeit without statistically significant changes (**Figure 4E**). Since peripheral cytokine levels as well as brain IL1 β mRNA levels were elevated, we further analysed levels of the fatty acid arachidonic acid as a precursor of eicosanoids and prostaglandins. Signals for arachidonic acid were comparable between genotypes and diets (while there may be a trend towards higher levels in CETPtg mice on cholesterol diet) suggesting overall low abundance of neuroinflammation in CETPtg mice at this age (**Figure 4B, F**).

Based on the MALDI-IMS results, the hippocampus shows elevated cholesterol levels in CETPtg mice. The hippocampus is a well-studied brain region responsible for various critical brain functions such as memory consolidation and its alterations are commonly associated with cognitive decline. To confirm the mass spectrometry results with a second independent approach and with higher resolution, we used filipin staining to assess cholesterol levels in the CA1, CA3, and dentate gyrus

(DG) regions of hippocampus (**Figure 4G**). Filipin staining in the hippocampus clearly labeled the plasma membranes in all conditions. The overall cholesterol levels assessed by intensity of filipin fluorescence was elevated by 15-25% in all hippocampal regions CETPtg mice as compared to wt mice on a high cholesterol diet (**Figure 4I-J**). Interestingly, the presence of CETP in CA3 and DG significantly increased cholesterol levels in the cholesterol-diet group as compared to CETPtg on a standard chow, suggesting location specific differences in cholesterol metabolism and/or transport (**Figure 4I-J**). Furthermore, at a high magnification, we noticed accumulated cholesterol deposits in brain sections only of CETPtg mice on the cholesterol diet (**Figure 4H**).

Transcriptional changes in CETPtg brains induced by presenilins

To investigate whether the increased brain cholesterol levels are a result of changes in the transcription of genes that induce cholesterol synthesis, we performed a microarray from purified astrocyte mRNA (**Figure 5**). The two extreme conditions of lowest and highest cholesterol content in the brain were chosen (i.e., wt mice on a control diet compared to CETPtg mice on cholesterol diet resulting in a ~25% cholesterol increase, (**Figure 4D, J**)). Cells positive for the glutamate aspartate transporter (GLAST), a specific marker of astrocytes, were enriched from freshly dissected and dissociated whole brains using the ACSA-1 MicroBead Kit. To verify the enrichment of astrocytes, approximately 8×10^5 cells were stained for the astrocyte marker, glial fibrillary acidic protein (GFAP), and analysed by flow cytometry revealing a purity of more than 80% across all samples (**Figure 5A**). Of note, there may be basal expression of GLAST in some neurons (39). Using total purified mRNA, CETP expression was validated in the astrocyte mRNA by qPCR (**Figure 5B**) and astrocyte transcripts were analysed on a Clariom S microarray. 595 genes were significantly up and 431 genes significantly down regulated at a threshold level of 1.5-fold change (**Figure 5C, D**). Interestingly, genes involved in cholesterol or lipid synthesis were not among the most differentially regulated genes (**Figure 5E**). In fact, such genes were downregulated such as HMGCR (1.57-fold down), SREBF1 (1.71-fold down), SREBF2 (1.84-fold down), and mevalonate kinase (MVK, 1.42-fold down). In

addition, mRNA levels of LDLR and LRP1 were reduced (**Figure 5E**). Overall, this data implies that it is unlikely that increased *de novo* cholesterol synthesis is responsible for the elevated cholesterol levels in CETP^{tg} mice.

Since we were interested to reveal if mice with humanised cholesterol metabolism show changes in the brain relevant to Alzheimer's disease, we analysed the effect of CETP on genes linked to Alzheimer's (**Figure 5F**). Seven genes were identified to be differentially expressed: Upregulated genes included 1) the prime Alzheimer's risk gene apolipoprotein E (ApoE, 1.57-fold up) involved in lipid transport, which is interesting since several epidemiological studies suggested an interaction between CETP and ApoE in the context of Alzheimer's disease (16,18); 2) The angiotensin-converting enzyme (ACE, 2.03-fold up) producing the vasoconstrictor angiotensin II, which is upregulated and implicated in hypoperfusion in Alzheimer's disease (40); 3) Caspase-8 (CASP8, 1.53-fold up) as a part of the apoptotic machinery, for which polymorphisms have been associated with Alzheimer's disease (41,42); and 4) IL1 β (1.46-fold up), an inflammatory cytokine that is elevated in Alzheimer's disease brains (43). Downregulated genes included 5) the insulin-degrading enzyme (IDE, 1.51-fold down), which has been implicated in the degradation of A β peptides and was associated with sporadic Alzheimer's disease (44); 6) TREM2 (2.34-fold down), which has been genetically linked to Alzheimer's disease, acts as a lipoprotein receptor and has been intensively studied in activated microglia (33). 7) Sortilin-related receptor 1 (SORL1, 1.42-fold down), which was described to shuttle APP away from subcellular locations of A β production (45). Together, all these changes are in line with pathological changes in Alzheimer's disease and imply that due to the presence of CETP several molecular changes co-occur. Next, we performed an upstream-regulator analysis, which identifies common regulators that may account for the overall changes in mRNA expression in the dataset. The top upstream regulator was the prostaglandin E2 EP4 subtype (*PTGER4*) as 24 downstream targets of *PTGER4* were differentially regulated (**Figure 5G**). *PTGER4* encodes for a G-protein coupled receptor that binds prostaglandin E2 (PGE₂) and has been associated with neurotoxicity and neuroinflammation (45,46). Most interestingly, the second and third hit of upstream regulators are

presenilin-1 and -2 (PSEN1 and PSEN2), the catalytic subunits of γ -secretase, an important protease in the etiology of Alzheimer's disease, which cleaves multiple substrates and is responsible for generating A β peptides. Presenilin-1 and -2 were identified by 21 and 14 known downstream target genes, respectively (**Figure 5G**). To validate the expression changes found for these target genes at the protein level, we performed immunohistochemistry on hippocampal sections for one of our major hits, the initiating factor of the classical complement cascade, C1q. All genes coding for C1q protein are downstream to PSEN1 and PSEN2 and are significantly upregulated (C1qA: 3.48-fold change, C1qB: 1.55-fold change and C1qC: 2.1-fold change). Moreover, C1q is an important marker of neurodegeneration and contributes to synapse loss in Alzheimer's disease (47,48). Immunohistochemistry for C1q protein revealed a significant increase in C1q protein expression throughout the hippocampus of high cholesterol-fed CETP^{tg} mice compared to wt and CETP^{tg} mice on a normal diet (**Figure 5H-I**). Overall, our results suggest that the presence of CETP and the subsequently 'humanised' cholesterol transport activates presenilin signaling and the complement system in the mouse brain.

CETP activates γ -secretase

Given the elevated brain cholesterol levels and the associated stimulation of γ -secretase-mediated signalling, we investigated if CETP activity stimulates γ -secretase activity *in vitro*. To this end, we took advantage of a well-known γ -secretase substrate, notch. Once the notch intracellular domain has been released by γ -secretase, it activates transcription of notch target genes, i.e., HES1 (Hes Family BHLH transcription factor 1) and p21 (cyclin dependent kinase inhibitor 1A) (49). We therefore expressed CETP or an inactive CETP mutant (L457/M459W (50)) in HEK293T cells and determined γ -secretase activity by quantifying notch-target gene expression by qPCR (**Figure 6A, B**). Indeed, active CETP increased HES1 and p21 expression, whereas the catalytically inactive CETP had no effect (**Figure 6B**). The data shows that CETP activity causes cellular changes that stimulate γ -secretase activity *in vitro* and *in vivo*.

Discussion

CETP-mediated increase in brain cholesterol

In this study, we aimed to understand effects of CETP on brain lipid composition and gene regulation.

Based on our analysis, CETP^{tg} mice show a lipoprotein profile in the blood that resembles much better the human lipoprotein profile and importantly shows a ~25% increase in brain cholesterol levels

as compared to wt. To our knowledge, this is the first report of a transgenic mouse model showing

elevated cholesterol levels to this extent. Some CETP^{tg} mice on the cholesterol diet showed

peripheral inflammation, but no elevated cytokine levels in total cortical mRNA, except for IL-1 β at 5

months of age and after a 3-month long 1% cholesterol diet. The enhanced inflammatory response in

liver and plasma could be attributed to higher cholesterol levels in immune cells where it was already

demonstrated that cholesterol augments, for instance, TLR receptor signalling, and modulates

immune cells surrounding tumors (51,52). Interestingly, most of the changed gene expression in

astrocytes related to inflammatory or immune-related genes. We focused on the complement factor

C1q, which is elevated in CETP^{tg} mice on a high cholesterol diet as compared to controls (**Figure**

5H, I). C1q is being increasingly discussed in the context of Alzheimer's disease (53). C1q was

originally viewed as the initiating component of the classical complement pathway. However, there is

increasing evidence that suggests various complement-independent roles for C1q in innate and

acquired immunity, as well as neuronal plasticity (54). As such, C1q mediates synapse pruning and

it is also associated with neuroprotective effects such as the upregulation of cholesterol metabolizing

genes and decreasing cellular cholesterol content (47,55). Thus, the elevated C1q levels in CETP^{tg}

mice could be a reaction to the elevated cholesterol levels aiming to eliminate excess cholesterol from

the brain.

We investigated if the increase of brain cholesterol arises from *de novo* synthesis in the brain, which

we could *not* confirm by transcriptome analysis. The elevated cholesterol levels may be explained by

one of the following alternative pathways. While most lipoprotein particles cannot cross the blood-

brain barrier, some lipid exchange between the brain and the blood can occur (2,56,57). It is well established that beneficial dietary w3-fatty acids enter the brain (58,59). In addition, 24S- and 27-hydroxysterols efficiently cross the blood-brain barrier and polymorphisms in 24S-hydroxylase were associated with Alzheimer's Disease (2,60). Lastly, HDL particles were described to be capable of transporting cholesterol into the brain via scavenger-receptor mediated transport or transcytosis (61,62). In addition, the function of CETP in the brain remains unclear. While CETP shuttles cholesterol between HDL and VLDL in the blood, those lipoprotein particles do not exist in the brain (7). In the brain, ApoE is the predominant lipoprotein and most lipoprotein particles are HDL-like in size and decorated with ApoE or ApoJ (8,63). While a role for CETP in the brain is not clear, it is likely that it is active as a lipid transporter. However, the interaction partners may differ, and it is a possibility that CETP is involved in cholesterol redistribution between cells or acts as intracellular shuttle between organelles. Further, CETP may be involved in the storage of lipids in microglia and astrocytes. In this line, the Morton laboratory reported a role of CETP in lipid droplet formation (64,65). We observed cholesterol accumulations in CETP^{tg} mice on a high cholesterol diet (**Figure 4H**), however, we could not determine the exact nature of such accumulations. Consequently, it is possible that lifetime exposure to CETP activity in the brain may cause an overall retention of cholesterol in the brain, leading to increased cholesterol levels observed in CETP^{tg} mice on either diet. It will be most interesting to reveal if blood-derived CETP, centrally expressed CETP, or both are responsible for the molecular changes of the brain described herein.

In the liver of CETP^{tg} mice, we observed an upregulation of ABCA7 and TREM2 as compared to wt mice. TREM2 mutations associate with Alzheimer's disease, and it was thus far discussed as an immune receptor in the brain, but it also acts as a lipoprotein receptor, particularly for ApoE-containing particles (66-68). However, two recent manuscripts linked ABCA7 and TREM2 to bile acid formation in the liver (69,70). Thus, the elevated ABCA7 and TREM2 levels in CETP^{tg} mice on cholesterol diet

in the liver may reflect an increase in bile acid formation. It is tempting to speculate that ABCA7 and TREM2 may be involved in cholesterol transport or redistribution in the brain.

Several Alzheimer-related changes are triggered in CETP^{tg} mice

Alzheimer's disease is the most common form of dementia and defined by the occurrence of amyloid plaques composed of A β peptides. A β peptides are generated from the amyloid precursor protein (APP) through two subsequent proteolytic cleavages. First, the ectodomain of APP is removed by β -secretase and then the membrane-bound C-terminal fragment is cleaved by γ -secretase (71-73). It is well established that higher cellular levels of cholesterol stimulate β - and γ -secretase activity (74-78). To date, the physiological function of APP as well as the trigger that leads to A β production remains unclear. However, it is evident that cellular pathways that stimulate A β production could qualify as the underlying mechanism leading to Alzheimer's disease. The CETP^{tg} mice analysed herein show a 'humanised' cholesterol metabolism but are not causatively linked to Alzheimer's disease. Curiously, the cerebral changes that we observed (high cholesterol levels, transcriptional changes, γ -secretase activity) resemble changes that have previously been described in Alzheimer's disease. The upstream regulator analysis of the microarray revealed the prostaglandin E₂ receptor EP4 (gene name PTGER4) as the most significant upstream regulator (**Figure 5G**). In the brain, the EP4 receptor binds prostaglandin E₂ (PGE₂) a key inflammatory mediator in response to circulating IL1 β matching our observations of EP4 as top upstream regulator (79). However, its role in mediating an inflammatory response is not completely clear as PGE₂ can have both pro- and anti-inflammatory effects (80-83). Yet, multiple studies have linked activation of EP4 with an increase in A β peptides and memory loss in the context of Alzheimer's disease (84,85). Such effects may be explained rather through stimulated γ -secretase activity than through conventional G-protein coupled receptor signalling. Hoshino *et. al* show that upon stimulation with PGE₂, EP4 is co-internalised with γ -secretase to endosomal and lysosomal compartments where γ -secretase activity is elevated (86). Such detrimental effects were abolished in EP4 knock-out animals or through pharmacological inhibition of EP4 (84). In line with this

mechanism, activation of γ -secretase activity was indeed observed as second and third top upstream regulators identified in CETPtg mice (**Figure 5G**). γ -Secretase activity is stimulated by membrane cholesterol and co-internalization with EP4 (74,87). It is important to note that while it has been well established that EP4 internalization occurs upon PGE₂ binding, the receptor also carries a cholesterol consensus motif and directly senses changes in cellular cholesterol levels (88). Interestingly, expression of CETP in cell culture models is already sufficient to increase γ -secretase activity. Consequently, it is likely that the effects on presenilins/ γ -secretase are downstream of the elevated cholesterol levels in the brain. The altered cholesterol transport, at least in the CETPtg model presented here, drives multiple molecular changes that recapitulate changes already described in Alzheimer's disease, suggesting that a deregulation of cholesterol homeostasis may underlie Alzheimer's disease pathology (**Figure 6C**).

Lipidomic studies have found that abnormal plasma lipid profiles, and consequently abnormal lipid biomarker panels, yield specific markers of Alzheimer's disease (89-91). However, most animal models focus on overexpression of mutated forms of human APP, presenilin or tau, involved in a further hallmark pathology of Alzheimer's disease. All these mouse models have low levels of circulating LDL due to the lack of CETP and therefore do not report on the impact of cholesterol transport on Alzheimer's pathology, which may have been underestimated thus far (22). Here, we report that mice expressing human CETP exhibit elevated levels of cholesterol in the brain. In the absence of APP or presenilin overexpression, CETPtg mice show a transcriptional profile that reflects a multitude of changes previously described in the Alzheimer's disease. Taken together, our data suggest that a mouse model expressing CETP and APP will be a valuable tool to unravel the molecular mechanisms between the peripheral and central cholesterol metabolism, ApoE and Alzheimer's disease.

Acknowledgements

We thank Dr. Bernard Robaire for Affymetrix software support to evaluate the microarray data, Elizabeth-Ann Kranjec for initial MALDI IMS measures, and Dr. Sandra Paschkowsky and Sasen Efrem for valuable feedback on the manuscript.

Author contribution

FO performed and analysed all experiments presented here with the exception of the MALDI IMS data that were acquired and analyzed by EY supervised by PC, and fillipin and C1q stains that were performed by NY supervised by ARdS. LMM designed the project. FO wrote draft, LMM, NY, PC, and EY edited and revised the manuscript. All Authors approved the manuscript for publication.

Conflict of interest

The authors declare no competing financial interests.

References

1. Dietschy, J. (2009) Central nervous system: cholesterol turnover, brain development and neurodegeneration. *Biol Chem* **390**, 287-293
2. Bjorkhem, I., and Meaney, S. (2004) Brain cholesterol: long secret life behind a barrier. *Arterioscler Thromb Vasc Biol* **24**, 806-815
3. Yao, Z., and McLeod, R. S. (1994) Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins. *Biochim Biophys Acta* **1212**, 152-166
4. Glomset, J. A. (1980) High-density lipoproteins in human health and disease. *Adv Intern Med* **25**, 91-116
5. Liu, M., Kuhel, D. G., Shen, L., Hui, D. Y., and Woods, S. C. (2012) Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. *Am J Physiol Regul Integr Comp Physiol* **303**, R903-908

- 553 6. Vance, J. (2012) Dysregulation of cholesterol balance in the brain: contribution to
554 neurodegenerative diseases. *Dis Model Mech* **5**, 746-755
- 555 7. Vance, J., Hayashi, H., and Karten, B. (2005) Cholesterol homeostasis in neurons and glial
556 cells. *Semin Cell Dev Biol* **16**, 193-212
- 557 8. Vance, J. E., and Hayashi, H. (2010) Formation and function of apolipoprotein E-containing
558 lipoproteins in the nervous system. *Biochim Biophys Acta* **1801**, 806-818
- 559 9. Holtzman, D., Herz, J., and Bu, G. (2012) Apolipoprotein e and apolipoprotein e receptors:
560 normal biology and roles in Alzheimer disease. *Cold Spring Harb Perspect Med* **2**, a006312
- 561 10. Zilversmit, D. B., Hughes, L. B., and Balmer, J. (1975) Stimulation of cholesterol ester
562 exchange by lipoprotein-free rabbit plasma. *Biochim Biophys Acta* **409**, 393-398
- 563 11. Chajek, T., and Fielding, C. J. (1978) Isolation and characterization of a human serum
564 cholesteryl ester transfer protein. *Proc Natl Acad Sci U S A* **75**, 3445-3449
- 565 12. Lagrost, L. (1994) Regulation of cholesteryl ester transfer protein (CETP) activity: review of in
566 vitro and in vivo studies. *Biochim Biophys Acta* **1215**, 209-236
- 567 13. Zhong, S., Sharp, D. S., Grove, J. S., Bruce, C., Yano, K., Curb, J. D., and Tall, A. R. (1996)
568 Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl
569 ester transfer protein gene despite increased HDL levels. *J Clin Invest* **97**, 2917-2923
- 570 14. Barzilai, N., Atzmon, G., Derby, C., Bauman, J., and Lipton, R. (2006) A genotype of
571 exceptional longevity is associated with preservation of cognitive function. *Neurology* **67**,
572 2170-2175
- 573 15. Barzilai, N., Atzmon, G., Schechter, C., Schaefer, E., Cupples, A., Lipton, R., Cheng, S., and
574 Shuldiner, A. (2003) Unique lipoprotein phenotype and genotype associated with exceptional
575 longevity. *JAMA* **290**, 2030-2040
- 576 16. Rodriguez, E., Mateo, I., Infante, J., Llorca, J., Berciano, J., and Combarros, O. (2006)
577 Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk
578 associated with APOE epsilon4 allele. *J Neurol* **253**, 181-185

- 579 17. Sanders, A., Wang, C., Katz, M., Derby, C., Barzilai, N., Ozelius, L., and Lipton, R. (2010)
580 Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene
581 with memory decline and incidence of dementia. *JAMA* **303**, 150-158
- 582 18. Sundermann, E. E., Wang, C., Katz, M., Zimmerman, M. E., Derby, C. A., Hall, C. B., Ozelius,
583 L. J., and Lipton, R. B. (2016) Cholesteryl ester transfer protein genotype modifies the effect
584 of apolipoprotein epsilon4 on memory decline in older adults. *Neurobiol Aging* **41**, 200 e207-
585 200 e212
- 586 19. Murphy, E. A., Roddey, J. C., McEvoy, L. K., Holland, D., Hagler, D. J., Jr., Dale, A. M., Brewer,
587 J. B., and Alzheimer's Disease Neuroimaging, I. (2012) CETP polymorphisms associate with
588 brain structure, atrophy rate, and Alzheimer's disease risk in an APOE-dependent manner.
589 *Brain Imaging Behav* **6**, 16-26
- 590 20. Wang, H., and Eckel, R. H. (2014) What are lipoproteins doing in the brain? *Trends Endocrinol*
591 *Metab* **25**, 8-14
- 592 21. Yamada, T., Kawata, M., Arai, H., Fukasawa, M., Inoue, K., and Sato, T. (1995) Astroglial
593 localization of cholesteryl ester transfer protein in normal and Alzheimer's disease brain
594 tissues. *Acta Neuropathol* **90**, 633-636
- 595 22. Steenbergen, R. H., Joyce, M. A., Lund, G., Lewis, J., Chen, R., Barsby, N., Douglas, D., Zhu,
596 L. F., Tyrrell, D. L., and Kneteman, N. M. (2010) Lipoprotein profiles in SCID/uPA mice
597 transplanted with human hepatocytes become human-like and correlate with HCV infection
598 success. *Am J Physiol Gastrointest Liver Physiol* **299**, G844-854
- 599 23. Jiang, X., Agellon, L., Walsh, A., Breslow, J., and Tall, A. (1992) Dietary cholesterol increases
600 transcription of the human cholesteryl ester transfer protein gene in transgenic mice.
601 Dependence on natural flanking sequences. *J Clin Invest* **90**, 1290-1295
- 602 24. Gauthier, B., Robb, M., Gaudet, F., Ginsburg, G. S., and McPherson, R. (1999)
603 Characterization of a cholesterol response element (CRE) in the promoter of the cholesteryl

604 ester transfer protein gene: functional role of the transcription factors SREBP-1a, -2, and YY1.
605 *J Lipid Res* **40**, 1284-1293

606 25. Groseclose, M. R., and Castellino, S. (2013) A mimetic tissue model for the quantification of
607 drug distributions by MALDI imaging mass spectrometry. *Anal Chem* **85**, 10099-10106

608 26. Dufresne, M., Thomas, A., Breault-Turcot, J., Masson, J. F., and Chaurand, P. (2013) Silver-
609 assisted laser desorption ionization for high spatial resolution imaging mass spectrometry of
610 olefins from thin tissue sections. *Anal Chem* **85**, 3318-3324

611 27. Schramm, T., Hester, Z., Klinkert, I., Both, J. P., Heeren, R. M. A., Brunelle, A., Laprevote, O.,
612 Desbenoit, N., Robbe, M. F., Stoeckli, M., Spengler, B., and Rompp, A. (2012) imzML--a
613 common data format for the flexible exchange and processing of mass spectrometry imaging
614 data. *J Proteomics* **75**, 5106-5110

615 28. Bemis, K. D., Harry, A., Eberlin, L. S., Ferreira, C., van de Ven, S. M., Mallick, P., Stolowitz,
616 M., and Vitek, O. (2015) Cardinal: an R package for statistical analysis of mass spectrometry-
617 based imaging experiments. *Bioinformatics* **31**, 2418-2420

618 29. Brown, M. S., Ye, J., Rawson, R. B., and Goldstein, J. L. (2000) Regulated intramembrane
619 proteolysis: a control mechanism conserved from bacteria to humans. *Cell* **100**, 391-398

620 30. Llorente-Cortes, V., Costales, P., Bernues, J., Camino-Lopez, S., and Badimon, L. (2006)
621 Sterol regulatory element-binding protein-2 negatively regulates low density lipoprotein
622 receptor-related protein transcription. *J Mol Biol* **359**, 950-960

623 31. Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S.,
624 Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., Holtzman, D. M., Cirrito, J. R., and
625 Colonna, M. (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's
626 disease model. *Cell* **160**, 1061-1071

627 32. Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J. C., Carrasquillo, M. M.,
628 Abraham, R., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Jones, N., Stretton,
629 A., Thomas, C., Richards, A., Ivanov, D., Widdowson, C., Chapman, J., Lovestone, S., Powell,

630 J., Proitsi, P., Lupton, M. K., Brayne, C., Rubinsztein, D. C., Gill, M., Lawlor, B., Lynch, A.,
631 Brown, K. S., Passmore, P. A., Craig, D., McGuinness, B., Todd, S., Holmes, C., Mann, D.,
632 Smith, A. D., Beaumont, H., Warden, D., Wilcock, G., Love, S., Kehoe, P. G., Hooper, N. M.,
633 Vardy, E. R., Hardy, J., Mead, S., Fox, N. C., Rossor, M., Collinge, J., Maier, W., Jessen, F.,
634 Ruther, E., Schurmann, B., Heun, R., Kolsch, H., van den Bussche, H., Heuser, I., Kornhuber,
635 J., Wiltfang, J., Dichgans, M., Frolich, L., Hampel, H., Gallacher, J., Hull, M., Rujescu, D.,
636 Giegling, I., Goate, A. M., Kauwe, J. S., Cruchaga, C., Nowotny, P., Morris, J. C., Mayo, K.,
637 Sleegers, K., Bettens, K., Engelborghs, S., De Deyn, P. P., Van Broeckhoven, C., Livingston,
638 G., Bass, N. J., Gurling, H., McQuillin, A., Gwilliam, R., Deloukas, P., Al-Chalabi, A., Shaw, C.
639 E., Tsolaki, M., Singleton, A. B., Guerreiro, R., Muhleisen, T. W., Nothen, M. M., Moebus, S.,
640 Jockel, K. H., Klopp, N., Wichmann, H. E., Pankratz, V. S., Sando, S. B., Aasly, J. O.,
641 Barcikowska, M., Wszolek, Z. K., Dickson, D. W., Graff-Radford, N. R., Petersen, R. C.,
642 Alzheimer's Disease Neuroimaging, I., van Duijn, C. M., Breteler, M. M., Ikram, M. A.,
643 DeStefano, A. L., Fitzpatrick, A. L., Lopez, O., Launer, L. J., Seshadri, S., consortium, C., Berr,
644 C., Champion, D., Epelbaum, J., Dartigues, J. F., Tzourio, C., Alperovitch, A., Lathrop, M.,
645 consortium, E., Feulner, T. M., Friedrich, P., Riehle, C., Krawczak, M., Schreiber, S., Mayhaus,
646 M., Nicolhaus, S., Wagenpfeil, S., Steinberg, S., Stefansson, H., Stefansson, K., Snaedal, J.,
647 Bjornsson, S., Jonsson, P. V., Chouraki, V., Genier-Boley, B., Hiltunen, M., Soininen, H.,
648 Combarros, O., Zelenika, D., Delepine, M., Bullido, M. J., Pasquier, F., Mateo, I., Frank-
649 Garcia, A., Porcellini, E., Hanon, O., Coto, E., Alvarez, V., Bosco, P., Siciliano, G., Mancuso,
650 M., Panza, F., Solfrizzi, V., Nacmias, B., Sorbi, S., Bossu, P., Piccardi, P., Arosio, B., Annoni,
651 G., Seripa, D., Pilotto, A., Scarpini, E., Galimberti, D., Brice, A., Hannequin, D., Licastro, F.,
652 Jones, L., Holmans, P. A., Jonsson, T., Riemenschneider, M., Morgan, K., Younkin, S. G.,
653 Owen, M. J., O'Donovan, M., Amouyel, P., and Williams, J. (2011) Common variants at
654 ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's
655 disease. *Nat Genet* **43**, 429-435

- 656 33. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C.,
657 Sassi, C., Kauwe, J. S., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., Williams,
658 J., Lambert, J. C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St George-
659 Hyslop, P., Singleton, A., Hardy, J., and Alzheimer Genetic Analysis, G. (2013) TREM2
660 variants in Alzheimer's disease. *N Engl J Med* **368**, 117-127
- 661 34. Iwamoto, N., Abe-Dohmae, S., Sato, R., and Yokoyama, S. (2006) ABCA7 expression is
662 regulated by cellular cholesterol through the SREBP2 pathway and associated with
663 phagocytosis. *J Lipid Res* **47**, 1915-1927
- 664 35. Wouters, K., van Gorp, P. J., Bieghs, V., Gijbels, M. J., Duimel, H., Lutjohann, D., Kerksiek,
665 A., van Kruchten, R., Maeda, N., Staels, B., van Bilsen, M., Shiri-Sverdlov, R., and Hofker, M.
666 H. (2008) Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in
667 hyperlipidemic mouse models of nonalcoholic steatohepatitis. *Hepatology* **48**, 474-486
- 668 36. Muller, N., Schulte, D. M., Turk, K., Freitag-Wolf, S., Hampe, J., Zeuner, R., Schroder, J. O.,
669 Gouni-Berthold, I., Berthold, H. K., Krone, W., Rose-John, S., Schreiber, S., and Laudes, M.
670 (2015) IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and
671 lipoprotein (a) synthesis in humans. *J Lipid Res* **56**, 1034-1042
- 672 37. Thomas, A., Charbonneau, J. L., Fournaise, E., and Chaurand, P. (2012) Sublimation of new
673 matrix candidates for high spatial resolution imaging mass spectrometry of lipids: enhanced
674 information in both positive and negative polarities after 1,5-diaminonaphthalene deposition.
675 *Anal Chem* **84**, 2048-2054
- 676 38. Caughlin, S., Park, D. H., Yeung, K. K., Cechetto, D. F., and Whitehead, S. N. (2017)
677 Sublimation of DAN Matrix for the Detection and Visualization of Gangliosides in Rat Brain
678 Tissue for MALDI Imaging Mass Spectrometry. *J Vis Exp*
- 679 39. Rothstein, J. D., Martin, L., Levey, A. I., Dykes-Hoberg, M., Jin, L., Wu, D., Nash, N., and
680 Kuncl, R. W. (1994) Localization of neuronal and glial glutamate transporters. *Neuron* **13**, 713-
681 725

- 682 40. Love, S., and Miners, J. S. (2016) Cerebral Hypoperfusion and the Energy Deficit in
683 Alzheimer's Disease. *Brain Pathol* **26**, 607-617
- 684 41. Rohn, T. T., Head, E., Nesse, W. H., Cotman, C. W., and Cribbs, D. H. (2001) Activation of
685 caspase-8 in the Alzheimer's disease brain. *Neurobiol Dis* **8**, 1006-1016
- 686 42. Rehker, J., Rodhe, J., Nesbitt, R. R., Boyle, E. A., Martin, B. K., Lord, J., Karaca, I., Naj, A.,
687 Jessen, F., Helisalmi, S., Soininen, H., Hiltunen, M., Ramirez, A., Scherer, M., Farrer, L. A.,
688 Haines, J. L., Pericak-Vance, M. A., Raskind, W. H., Cruchaga, C., Schellenberg, G. D.,
689 Joseph, B., and Brkanac, Z. (2017) Caspase-8, association with Alzheimer's Disease and
690 functional analysis of rare variants. *PLoS One* **12**, e0185777
- 691 43. Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V., Perrot, L. J., White, C. L., 3rd,
692 and Araoz, C. (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down
693 syndrome and Alzheimer disease. *Proc Natl Acad Sci U S A* **86**, 7611-7615
- 694 44. Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R.,
695 Safavi, A., Hersh, L. B., and Selkoe, D. J. (1998) Insulin-degrading enzyme regulates
696 extracellular levels of amyloid beta-protein by degradation. *J Biol Chem* **273**, 32730-32738
- 697 45. Andersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim,
698 C. A., Breiderhoff, T., Jansen, P., Wu, X., Bales, K. R., Cappai, R., Masters, C. L., Gliemann,
699 J., Mufson, E. J., Hyman, B. T., Paul, S. M., Nykjaer, A., and Willnow, T. E. (2005) Neuronal
700 sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor
701 protein. *Proc Natl Acad Sci U S A* **102**, 13461-13466
- 702 46. Fujikawa, R., Higuchi, S., Nakatsuji, M., Yasui, M., Ikedo, T., Nagata, M., Hayashi, K., Yokode,
703 M., and Minami, M. (2017) Deficiency in EP4 Receptor-Associated Protein Ameliorates
704 Abnormal Anxiety-Like Behavior and Brain Inflammation in a Mouse Model of Alzheimer
705 Disease. *Am J Pathol* **187**, 1848-1854
- 706 47. Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K.
707 M., Shi, Q., Rosenthal, A., Barres, B. A., Lemere, C. A., Selkoe, D. J., and Stevens, B. (2016)

708 Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science*
709 **352**, 712-716

710 48. Afagh, A., Cummings, B. J., Cribbs, D. H., Cotman, C. W., and Tenner, A. J. (1996)
711 Localization and cell association of C1q in Alzheimer's disease brain. *Exp Neurol* **138**, 22-32

712 49. Jarriault, S., Brou, C., Logeat, F., Schroeter, E. H., Kopan, R., and Israel, A. (1995) Signalling
713 downstream of activated mammalian Notch. *Nature* **377**, 355-358

714 50. Qiu, X., Mistry, A., Ammirati, M., Chrnyk, B., Clark, R., Cong, Y., Culp, J., Danley, D.,
715 Freeman, T., Geoghegan, K., Griffor, M., Hawrylik, S., Hayward, C., Hensley, P., Hoth, L.,
716 Karam, G., Lira, M., Lloyd, D., McGrath, K., Stutzman-Engwall, K., Subashi, A., Subashi, T.,
717 Thompson, J., Wang, I., Zhao, H., and Seddon, A. (2007) Crystal structure of cholesteryl ester
718 transfer protein reveals a long tunnel and four bound lipid molecules. *Nat Struct Mol Biol* **14**,
719 106-113

720 51. Yang, W., Bai, Y., Xiong, Y., Zhang, J., Chen, S., Zheng, X., Meng, X., Li, L., Wang, J., Xu,
721 C., Yan, C., Wang, L., Chang, C. C., Chang, T. Y., Zhang, T., Zhou, P., Song, B. L., Liu, W.,
722 Sun, S. C., Liu, X., Li, B. L., and Xu, C. (2016) Potentiating the antitumour response of CD8(+)
723 T cells by modulating cholesterol metabolism. *Nature* **531**, 651-655

724 52. Tall, A. R., and Yvan-Charvet, L. (2015) Cholesterol, inflammation and innate immunity. *Nat*
725 *Rev Immunol* **15**, 104-116

726 53. Reichwald, J., Danner, S., Wiederhold, K. H., and Staufenbiel, M. (2009) Expression of
727 complement system components during aging and amyloid deposition in APP transgenic
728 mice. *J Neuroinflammation* **6**, 35

729 54. Thielens, N. M., Tedesco, F., Bohlson, S. S., Gaboriaud, C., and Tenner, A. J. (2017) C1q: A
730 fresh look upon an old molecule. *Mol Immunol* **89**, 73-83

731 55. Benoit, M. E., and Tenner, A. J. (2011) Complement protein C1q-mediated neuroprotection is
732 correlated with regulation of neuronal gene and microRNA expression. *J Neurosci* **31**, 3459-
733 3469

734 56. Bjorkhem, I., Lutjohann, D., Diczfalussy, U., Stahle, L., Ahlborg, G., and Wahren, J. (1998)
735 Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence
736 for a cerebral origin of most of this oxysterol in the circulation. *J Lipid Res* **39**, 1594-1600

737 57. Zlokovic, B. V. (2008) The blood-brain barrier in health and chronic neurodegenerative
738 disorders. *Neuron* **57**, 178-201

739 58. Nguyen, L. N., Ma, D., Shui, G., Wong, P., Cazenave-Gassiot, A., Zhang, X., Wenk, M. R.,
740 Goh, E. L., and Silver, D. L. (2014) Mfsd2a is a transporter for the essential omega-3 fatty acid
741 docosahexaenoic acid. *Nature* **509**, 503-506

742 59. Ouellet, M., Emond, V., Chen, C. T., Julien, C., Bourasset, F., Oddo, S., LaFerla, F., Bazinet,
743 R. P., and Calon, F. (2009) Diffusion of docosahexaenoic and eicosapentaenoic acids through
744 the blood-brain barrier: An in situ cerebral perfusion study. *Neurochem Int* **55**, 476-482

745 60. Bjorkhem, I. (2006) Crossing the barrier: oxysterols as cholesterol transporters and metabolic
746 modulators in the brain. *J Intern Med* **260**, 493-508

747 61. Balazs, Z., Panzenboeck, U., Hammer, A., Sovic, A., Quehenberger, O., Malle, E., and Sattler,
748 W. (2004) Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-
749 tocopherol by an in vitro blood-brain barrier model. *J Neurochem* **89**, 939-950

750 62. Stukas, S., Robert, J., Lee, M., Kulic, I., Carr, M., Tourigny, K., Fan, J., Namjoshi, D., Lemke,
751 K., DeValle, N., Chan, J., Wilson, T., Wilkinson, A., Chapanian, R., Kizhakkedathu, J. N.,
752 Cirrito, J. R., Oda, M. N., and Wellington, C. L. (2014) Intravenously injected human
753 apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus. *J Am Heart*
754 *Assoc* **3**, e001156

755 63. Fagan, A. M., Holtzman, D. M., Munson, G., Mathur, T., Schneider, D., Chang, L. K., Getz, G.
756 S., Reardon, C. A., Lukens, J., Shah, J. A., and LaDu, M. J. (1999) Unique lipoproteins
757 secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice.
758 *J Biol Chem* **274**, 30001-30007

759 64. Izem, L., and Morton, R. (2001) Cholesteryl ester transfer protein biosynthesis and cellular
760 cholesterol homeostasis are tightly interconnected. *J Biol Chem* **276**, 26534-26541

761 65. Izem, L., and Morton, R. (2007) Possible role for intracellular cholesteryl ester transfer protein
762 in adipocyte lipid metabolism and storage. *J Biol Chem* **282**, 21856-21865

763 66. Kober, D. L., Stuchell-Brereton, M. D., Kluender, C. E., Dean, H. B., Strickland, M. R.,
764 Steinberg, D. F., Nelson, S. S., Baban, B., Holtzman, D. M., Frieden, C., Alexander-Brett, J.,
765 Roberson, E. D., Song, Y., and Brett, T. J. (2020) Functional insights from biophysical study
766 of TREM2 interactions with apoE and Abeta1-42. *Alzheimers Dement*

767 67. Fitz, N. F., Wolfe, C. M., Playso, B. E., Biedrzycki, R. J., Lu, Y., Nam, K. N., Lefterov, I., and
768 Koldamova, R. (2020) Trem2 deficiency differentially affects phenotype and transcriptome of
769 human APOE3 and APOE4 mice. *Mol Neurodegener* **15**, 41

770 68. Li, Z., Del-Aguila, J. L., Dube, U., Budde, J., Martinez, R., Black, K., Xiao, Q., Cairns, N. J.,
771 Dominantly Inherited Alzheimer, N., Dougherty, J. D., Lee, J. M., Morris, J. C., Bateman, R.
772 J., Karch, C. M., Cruchaga, C., and Harari, O. (2018) Genetic variants associated with
773 Alzheimer's disease confer different cerebral cortex cell-type population structure. *Genome*
774 *Med* **10**, 43

775 69. MahmoudianDehkordi, S., Arnold, M., Nho, K., Ahmad, S., Jia, W., Xie, G., Louie, G., Kueider-
776 Paisley, A., Moseley, M. A., Thompson, J. W., St John Williams, L., Tenenbaum, J. D., Blach,
777 C., Baillie, R., Han, X., Bhattacharyya, S., Toledo, J. B., Schafferer, S., Klein, S., Koal, T.,
778 Risacher, S. L., Kling, M. A., Motsinger-Reif, A., Rotroff, D. M., Jack, J., Hankemeier, T.,
779 Bennett, D. A., De Jager, P. L., Trojanowski, J. Q., Shaw, L. M., Weiner, M. W., Doraiswamy,
780 P. M., van Duijn, C. M., Saykin, A. J., Kastenmuller, G., Kaddurah-Daouk, R., Alzheimer's
781 Disease Neuroimaging, I., and the Alzheimer Disease Metabolomics, C. (2019) Altered bile
782 acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for
783 gut microbiome. *Alzheimers Dement* **15**, 76-92

- 784 70. Nho, K., Kueider-Paisley, A., MahmoudianDehkordi, S., Arnold, M., Risacher, S. L., Louie, G.,
785 Blach, C., Baillie, R., Han, X., Kastenmuller, G., Jia, W., Xie, G., Ahmad, S., Hankemeier, T.,
786 van Duijn, C. M., Trojanowski, J. Q., Shaw, L. M., Weiner, M. W., Doraiswamy, P. M., Saykin,
787 A. J., Kaddurah-Daouk, R., Alzheimer's Disease Neuroimaging, I., and the Alzheimer Disease
788 Metabolomics, C. (2019) Altered bile acid profile in mild cognitive impairment and Alzheimer's
789 disease: Relationship to neuroimaging and CSF biomarkers. *Alzheimers Dement* **15**, 232-244
- 790 71. Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M.,
791 Dovey, H. F., Frigon, N., Hong, J., Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J.,
792 Lieberburg, I., Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D., Seubert, P.,
793 Suomensari, S. M., Wang, S., Walker, D., Zhao, J., McConlogue, L., and John, V. (1999)
794 Purification and cloning of amyloid precursor protein beta-secretase from human brain. *Nature*
795 **402**, 537-540
- 796 72. Vassar, R., Bennett, B., Babu-Khan, S., Kahn, S., Mendiaz, E., Denis, P., Teplow, D., Ross,
797 S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski,
798 M., Biere, A., Curran, E., Burgess, T., Louis, J., Collins, F., Treanor, J., Rogers, G., and Citron,
799 M. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the
800 transmembrane aspartic protease BACE. *Science* **286**, 735-741
- 801 73. Zhao, G., Tan, J., Mao, G., Cui, M., and Xu, X. (2007) The same gamma-secretase accounts
802 for the multiple intramembrane cleavages of APP. *J Neurochem* **100**, 1234-1246
- 803 74. Jung, J. I., Price, A. R., Ladd, T. B., Ran, Y., Park, H. J., Ceballos-Diaz, C., Smithson, L. A.,
804 Hochhaus, G., Tang, Y., Akula, R., Ba, S., Koo, E. H., Shapiro, G., Felsenstein, K. M., and
805 Golde, T. E. (2015) Cholestenoic acid, an endogenous cholesterol metabolite, is a potent
806 gamma-secretase modulator. *Mol Neurodegener* **10**, 29
- 807 75. Osenkowski, P., Ye, W., Wang, R., Wolfe, M., and Selkoe, D. (2008) Direct and potent
808 regulation of gamma-secretase by its lipid microenvironment. *J Biol Chem* **283**, 22529-22540

- 809 76. Das, U., Scott, D. A., Ganguly, A., Koo, E. H., Tang, Y., and Roy, S. (2013) Activity-induced
810 convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent
811 pathway. *Neuron* **79**, 447-460
- 812 77. Grimm, M., Grimm, H., Tomic, I., Beyreuther, K., Hartmann, T., and Bergmann, C. (2008)
813 Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered
814 cholesterol levels. *J Biol Chem* **283**, 11302-11311
- 815 78. Hui, L., Chen, X., and Geiger, J. D. (2012) Endolysosome involvement in LDL cholesterol-
816 induced Alzheimer's disease-like pathology in primary cultured neurons. *Life Sci* **91**, 1159-
817 1168
- 818 79. Fujikawa, R., Higuchi, S., Nakatsuji, M., Yasui, M., Ikedo, T., Nagata, M., Yokode, M., and
819 Minami, M. (2016) EP4 Receptor-Associated Protein in Microglia Promotes Inflammation in
820 the Brain. *Am J Pathol* **186**, 1982-1988
- 821 80. Echeverria, V., Clerman, A., and Dore, S. (2005) Stimulation of PGE receptors EP2 and EP4
822 protects cultured neurons against oxidative stress and cell death following beta-amyloid
823 exposure. *Eur J Neurosci* **22**, 2199-2206
- 824 81. Woodling, N. S., and Andreasson, K. I. (2016) Untangling the Web: Toxic and Protective
825 Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease. *ACS Chem*
826 *Neurosci* **7**, 454-463
- 827 82. Shi, J., Johansson, J., Woodling, N. S., Wang, Q., Montine, T. J., and Andreasson, K. (2010)
828 The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate
829 immunity. *J Immunol* **184**, 7207-7218
- 830 83. Woodling, N. S., Wang, Q., Priyam, P. G., Larkin, P., Shi, J., Johansson, J. U., Zagol-Ikapitte,
831 I., Bouteaud, O., and Andreasson, K. I. (2014) Suppression of Alzheimer-associated
832 inflammation by microglial prostaglandin-E2 EP4 receptor signaling. *J Neurosci* **34**, 5882-5894
- 833 84. Hoshino, T., Namba, T., Takehara, M., Murao, N., Matsushima, T., Sugimoto, Y., Narumiya,
834 S., Suzuki, T., and Mizushima, T. (2012) Improvement of cognitive function in Alzheimer's

835 disease model mice by genetic and pharmacological inhibition of the EP(4) receptor. *J*
836 *Neurochem* **120**, 795-805

837 85. Li, X., Montine, K. S., Keene, C. D., and Montine, T. J. (2015) Different mechanisms of
838 apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering
839 receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of
840 microglia. *FASEB J* **29**, 1754-1762

841 86. Hoshino, T., Namba, T., Takehara, M., Nakaya, T., Sugimoto, Y., Araki, W., Narumiya, S.,
842 Suzuki, T., and Mizushima, T. (2009) Prostaglandin E2 stimulates the production of amyloid-
843 beta peptides through internalization of the EP4 receptor. *J Biol Chem* **284**, 18493-18502

844 87. Marquer, C., Devaues, V., Cossec, J. C., Liot, G., Lecart, S., Saudou, F., Duyckaerts, C.,
845 Leveque-Fort, S., and Potier, M. C. (2011) Local cholesterol increase triggers amyloid
846 precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. *FASEB J* **25**, 1295-
847 1305

848 88. Hanson, M. A., Cherezov, V., Griffith, M. T., Roth, C. B., Jaakola, V. P., Chien, E. Y.,
849 Velasquez, J., Kuhn, P., and Stevens, R. C. (2008) A specific cholesterol binding site is
850 established by the 2.8 Å structure of the human beta2-adrenergic receptor. *Structure* **16**, 897-
851 905

852 89. Zarrouk, A., Debbabi, M., Bezine, M., Karym, E. M., Badreddine, A., Rouaud, O., Moreau, T.,
853 Cherkaoui-Malki, M., El Ayeb, M., Nasser, B., Hammami, M., and Lizard, G. (2018) Lipid
854 Biomarkers in Alzheimer's Disease. *Curr Alzheimer Res* **15**, 303-312

855 90. Kosicek, M., and Hecimovic, S. (2013) Phospholipids and Alzheimer's disease: alterations,
856 mechanisms and potential biomarkers. *Int J Mol Sci* **14**, 1310-1322

857 91. Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H.,
858 Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., Nazar, M. D., Rich, S. A., Berlau, D.
859 J., Peltz, C. B., Tan, M. T., Kawas, C. H., and Federoff, H. J. (2014) Plasma phospholipids
860 identify antecedent memory impairment in older adults. *Nat Med* **20**, 415-418

861 **Figure legends**

862 **Figure 1: Dietary cholesterol intake induces CETP expression:** **A:** Feeding schedule & study
 863 design. Wt and CETP^{tg} animals were fed for 1 month starting at the age of 2 months. Biochemical
 864 analyses were performed after 3 months of age. **B:** CETP activity of CETP^{tg} or wt animals was
 865 measured from 1 μ L plasma using the fluorescence-based CETP activity assay (Roar biomedical).
 866 n=6-14, mean $\pm$ SEM; 2-way ANOVA, Tukey's multiple comparison. **C:** Relative normalised CETP
 867 expression. RT-qPCR of liver samples at the age of 5 months. n=5-8, mean $\pm$ SEM; 2-way ANOVA,
 868 Tukey's multiple comparison. **D:** CETP western blot from liver lysates. Liver lysates were separated
 869 on 10% SDS-PA gels. CETP was detected using the TP2 monoclonal antibody. **E:** Quantification of
 870 CETP western blots as shown in **D:** n=8, mean $\pm$ SEM; Students T-test. **F-I:** Plasma lipoprotein
 871 analysis: **F:** HDL-C, **G:** LDL-C, **H:** total cholesterol **I:** and triglycerides from mouse plasma samples.
 872 Plasma samples were analysed on a COBAS Integra 400 Plus (ROCHE) analyser using the following
 873 kits: COBAS INTEGRA CHOL 2, COBAS INTEGRA HDL-C gen3, and COBAS Integra TRIG GPO
 874 250, respectively. The levels of LDL-C were calculated using the Friedewald formula: [total
 875 cholesterol] – [HDL-C] – [TG/2.2]. n=6-14. mean $\pm$ SEM; 2-way ANOVA, Tukey's multiple comparison.
 876 **J:** Mouse weight increase: Net weight increase of wt and CETP^{tg} mice during the feeding period.

877

878 **Figure 2: CETP promotes ABCA7 and TREM2 expression in the liver:** **A:** Feeding schedule &
 879 study design. Wt and CETP^{tg} mice were fed for 3 months starting at the age of 2 months. Biochemical
 880 analyses were performed at 5 months. **B-D:** Normalized RT-qPCR from mouse liver tissue. **B:**
 881 HMGCR, **C:** LDLR and **D:** LRP1 expression, n=6-14, mean $\pm$ SEM; 2-way ANOVA, Tukey's multiple
 882 comparison. **E:** Western blot analysis of ABCA7 and TREM2 from liver lysates. Antibodies used:
 883 rabbit-anti-GAPDH (14C10, Cell Signaling), anti-TREM2 (Mab1729 R&D systems) and anti-ABCA7
 884 (polyclonal, Thermo Fisher), n=6; mean $\pm$ SEM, Students T-test. **F-I:** Expression analysis of ABCA7
 885 and TREM2 from liver samples. Normalized RT-qPCR levels of liver **F:** ABCA7 and **H:** TREM2; n=6-

886 14, mean $\pm$ SEM; 2-way ANOVA, Tukey's multiple comparison. Western blot quantification of **G**:
887 ABCA7 and **I**: TREM2; n=6; mean $\pm$ SEM, Students T-test.

888

889 **Figure 3: CETP activity promotes peripheral inflammation: A, B:** Plasma cytokine levels. **A:** TNF α
890 and **B:** IL1 β measured in 25 μ L plasma using a multiplex ELISA (mesoscale discoveries); n=6-11.
891 mean $\pm$ SEM; 2-way ANOVA, Tukey's multiple comparison. **C-F:** RT-qPCR of liver samples from 5-
892 month old mice. Normalised expression of: **C:** TNF α , **D:** IL1 β , **E:** TLR4 and **F:** IL6 expression; n=6-
893 14, mean $\pm$ SEM; 2-way ANOVA, Tukey's multiple comparison. **G-K:** Cytokine mRNA expression in
894 brain samples by normalized RT-qPCR: **G:** CETP, **H:** TNF α , **I:** IL6, **J:** IL1 β and **K:** TLR4 expression;
895 n=6-10. mean $\pm$ SEM; 2-way ANOVA, Tukey's multiple comparison.

896

897 **Figure 4: CETP changes the brain cholesterol composition: A, B:** MALDI IMS on sagittal brain
898 sections of 5-month-old wt and CETP^{tg} brains. **A:** Heatmap representation of peak intensities
899 corresponding to cholesterol (m/z 493 [M+107Ag]⁺) and **B** arachidonic acid (m/z 411 [M+107Ag]⁺).
900 Please note the color scale with white and red depicting highest intensities. **C:** Whole brain sagittal
901 section representing regions of interest selected for 'whole brain' or hippocampal (HC) quantification.
902 **D, E:** Quantification of peak intensities corresponding to cholesterol from whole brain (**D**) and
903 hippocampus (**E**). **F:** Quantification of peak intensities corresponding to arachidonic acid from whole
904 brain; all n=3, mean $\pm$ SEM; Students T-test. **G:** Coronal view of mouse brain section showing
905 hippocampal regions of CA1, CA3, and DG. The blue inset shows the portion of DG that was selected
906 for demonstrating representative images. **H:** Consecutive confocal stacks from the hippocampus of
907 1% cholesterol-fed CETP^{tg} mice showing multiple filipin-bound cholesterol deposits. Insets show
908 enlarged views of areas with cholesterol deposits. **I:** representative images of filipin staining in brain
909 sections of wt and CETP^{tg} mice on standard and high cholesterol diet. **J:** Quantifications of filipin
910 fluorescent intensities in different hippocampal regions; n=3, mean $\pm$ SEM, two-way ANOVA followed
911 by Bonferroni's multiple comparisons test. Scale bars=100 μ m.

912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937

Figure 5: Transcriptional changes in CETPtg brain induced by presenilins: **A:** Flow cytometry analysis of astrocyte purification from 5-months-old mouse brains. GLAST-positive astrocytes were stained with GFAP. More than 80% of purified cells were GFAP positive. **B:** CETP RT-qPCR of astrocyte mRNA, n=2-3. mean $\pm$ SEM; 2-way ANOVA. **C:** Volcano plot of the mouse microarray results. Each dot represents an individual gene. The p-value of plotted against the gene regulation fold change of the corresponding gene. P-values cut-off for significance was set to <0.05 . **D:** Overall, 595 genes were found to be significantly up-regulated and 431 genes were found to be significantly down-regulated in our data set. **E:** Genes involved in the *de novo* synthesis of cholesterol, generation of arachidonic acid and lipoprotein receptors. **F:** Alzheimer's disease risk genes regulated in our data set. **G:** Pathways analysis of upstream regulators. Analyzing the fold changes in the dataset, PTGER4, presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are the top 3 predicted upstream regulators. A total of 21 genes that have been reported to be regulated via PS1 and have been found in our dataset. 14 of these genes have also been reported to be regulated via PS2 (highlighted in blue). Upstream regulator analysis was performed using ingenious pathway analysis. **H:** Representative images of astrocytes (green) and C1q (red) immunostaining in brain sections of wt and CETPtg mice on normal and high cholesterol diet. **I:** Quantifications of C1q fluorescent intensities in hippocampus n=3, mean $\pm$ SEM, two-way ANOVA followed by Bonferroni's multiple comparisons test. Scale bar=100 μ m. **NCBI gene numbers:** HMGCR: 15357; SREBF1: 20787; SREBF2: 20788; MVK: 17855; LRP1: 16971; LDLR: 16835; IDE: 15925; TREM2: 83433; IL1B: 16176; CASP8: 12370; ACE: 11421; APOE: 11816; SORL1: 20660; C1QA: 20660; CD74: 16149; CTSS: 13040; C1QC: 12262; CTSZ: 64138; Erdr1: 170942; SELPLG: 20345; C3AR1: 12267; C1QB: 12260; CD9: 12527; KIF5B: 16573; ENPP2: 18606; SLC38A2: 67760; HLA-E: 15040; WARS: 22375; FOXO3: 56484; RELN: 19699; BDNF: 12064; FMN2: 54418; CUEDC1: 103841; GDF11: 14561

938 **Figure 6: CETP activates γ -secretase**

939 **A:** CETP activity assay of HEK293T cells transfected with wild type (wt) CETP or an inactive mutant
 940 (CETP M457/L459W). N=3, mean $\pm$ SEM, students-T test **B:** Normalised relative expression of CETP,
 941 HES1 and p21; n=3, mean $\pm$ SEM, students T-test. **C:** Schematic representation of changes observed
 942 in liver, plasma and brain in CETP^{tg} animals as compared to wild type.

943

944

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6